Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TAP buyout leaves Prevacid switch deal intact

This article was originally published in The Tan Sheet

Executive Summary

Novartis Consumer Health remains "very committed to the Rx-to-OTC switch" of TAP Pharmaceutical Products' proton pump inhibitor Prevacid, the firm told "The Tan Sheet" March 20. Novartis reaffirmed its commitment to switching the hearthburn drug after Japanese drug firm Takeda announced March 19 it obtained a 100 percent stake in TAP when it bought out Abbott's 50 percent share of the joint venture. According to terms of the deal, Takeda will get the rights to Rx Prevacid. TAP will be integrated into Takeda's existing U.S. subsidiaries, which will establish Takeda America Holdings, the Japanese company says. Novartis Consumer Healthcare acquired the trademark and intellectual property rights for OTC Prevacid (lansoprazole) from TAP in December 2005, at which time Novartis announced plans for a switch in 2009 when the drug's patent expires (1"The Tan Sheet" Jan. 2, 2006, p. 6)...

You may also be interested in...



TAP Licenses Prevacid To Novartis For 2009 Switch

Novartis is developing TAP's Prevacid prescription heartburn and GERD therapy for a 2009 switch to OTC status, the firms announced Dec. 20

‘A Forever Battle:’ Patent Reform, Launch Prices, And Where Lower Rx Price Advocates Will Go Next

Pharma’s opponents believe passage of the Inflation Reduction Act represents a momentum shift that will make it easier for politicians (even some Republicans) to take on the industry. They’ll need to count on that as they still have a long list of targets ahead on their lower-drug pricing agenda.

Finance Watch: Karuna, Cerevel And Others Benefit From Improving Biotech Sentiment

Good news in the biopharma industry and the US economy gave public drug developers the boost they needed to raise cash, including Karuna’s $750m offering. Private company financings slowed during the second week of August, but Prellis and Vector BioPharma raised venture capital.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS101493

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel